In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
- 1 December 2015
- Vol. 33 (51) , 7415-7422
Abstract
No abstract availableKeywords
Funding Information
- USA Department of Defense Breast Cancer Research Program (W81XWH-11-1-0532)
- Chemotherapy Foundation
- Breast Cancer Alliance
- Breast Cancer Research Foundation
- Department of Defense Breast Cancer Research Program (W81XWH-13-1-0012)
- USA Department of Defense Breast Cancer Research Program (W81XWH-11-1-0530)
- NIH (R01 CA161891)
- Breast Cancer Research Foundation
- NIH (5P30CA016087)
This publication has 97 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4Science, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Chemotherapy and radiotherapy: Cryptic anticancer vaccinesSeminars in Immunology, 2010
- Systemic effects of local radiotherapyThe Lancet Oncology, 2009
- CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patientsProceedings of the National Academy of Sciences, 2008
- The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapyImmunological Reviews, 2007
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006